International data centre strategy for pharmaceutical giant
This pharmaceutical giant employs nearly 9,000 people in over 120 countries, with revenues in excess of $3.4 Billion. Its companies share a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe.
The Group has a technology estate that has grown organically through acquisition. The majority of its data centre sites have a small footprint, often co-located alongside offices. Spread across the world, these edge/regional hubs have limited local resource to manage them.
Keysource was asked to help the organisation to review its strategy, providing global consultancy of its edge estate. This involved undertaking a three-month assessment of 11 data centres in America, Hong Kong, Canada, China, Australia and in Britain to provide an audit of its IT infrastructure.
This review included an assessment of the data centre estate against a number of different national and international industry standards. The team also developed a road map for investing in the on-premise facilities that detailed where capex would be best directed to support the client’s’ wider IT transformation strategy. Keysource is now providing continued ongoing support following the recommendation, advising on actions from the audit and on service continuity.
Audit of 11 critical data centres across 6 countries against a common standard.
Development of international data centre strategy, complete with a investment roadmap.
Supporting the wider IT transformation strategy.
“This was a challenging brief covering a number of very different geographies and facilities and we needed a partner with specialist skills and knowledge.We are extremely happy with both the quality and speed of the work undertaken by Keysource. These critical environment specialists delivered acomprehensive audit across some of our key data centres, assessing them against the relevant standards and advising on best practice. This has provided valuable input for our international strategy and IT Transformation plans and we are pleased to be continuing our working relationship.”
— Spokesperson for this pharmaceutical giant